In gout, the drug decisions for sufferers stay restricted. The historical past of this subject contains many molecules that fell brief within the clinic or available on the market for security causes. James Mackay is aware of firsthand having led an organization that developed two of these withdrawn merchandise.
Mackay is again to strive once more. He’s now CEO of Crystalys Therapeutics, whose important asset is an in-licensed gout drug candidate with validation from its approval in a number of Asian international locations and extra security information from real-world use in these areas. On Tuesday, Crystalys revealed $205 million raised for Part 3 checks that would assist plans to finally convey this small molecule to sufferers within the U.S. and different markets.
Gout, a standard type of inflammatory arthritis, stems from excessive uric acid ranges within the blood that types crystals in joints and surrounding tissue, inflicting irritation and ache. The dysfunction is characterised by sudden assaults of ache and swelling within the joints known as gout flares. Sufferers with uncontrolled gout for an extended time frame develop deposits of uric acid within the joints, which is named gout tophus. These tophi is probably not painful, however they will impair joint motion and seem disfiguring.
The usual drug therapy for gout is allopurinol, a 60-year-old remedy that inhibits an enzyme key to producing uric acid. This tablet helps solely about 40% of gout sufferers, Mackay stated. San Diego-based Crystalys takes a distinct method with its drug, dotinurad. The oral small molecule is designed to dam URAT1, a protein answerable for the reabsorption of uric acid within the kidney. Usually, individuals excrete extra uric acid of their urine. Dotinurad is meant to assist gout sufferers do this.
“If you happen to block the transporter [protein], you mainly urinate out extra uric acid,” Mackay stated. “What’s good about its mechanism of motion is it immediately impacts the principle reason behind gout, which is the shortcoming to excrete sufficient uric acid. Mainly, it should trigger you to excrete extra and due to this fact scale back the extent of uric acid within the physique.”
Mackay is accustomed to URAT1 inhibitors as a result of he developed them at a earlier firm, Ardea Biosciences. Ardea’s lead drug candidate, lesinurad, reached Part 3 growth in gout when the biotech was acquired by AstraZeneca in 2012 for about $1 billion. In 2015, the FDA accepted the drug, which reached the market beneath the model identify Zurampic. That drug and the mix of lesinurad and allopurinol, branded as Duzallo, had been later withdrawn from the marketplace for enterprise causes. Mackay stated renal toxicity dangers made commercializing these medicine difficult. He doesn’t count on these issues for dotinurad, which has a security and efficacy profile outlined by its use in additional than 1.2 million gout sufferers in Japan.
Dotinurad was found and developed by Japanese firm Fuji Yakuhin, which steered the molecule to a regulatory approval in its residence nation in 2020. Eisai holds rights to the drug in a number of different Asian international locations. In 2021, Fortress Bio subsidiary Urica Therapeutics acquired U.S. and European rights to dotinurad; the next 12 months, the license settlement was expanded to the Center East and North Africa. Urica superior dotinurad so far as Part 1 testing in wholesome volunteers and gout sufferers.
Mackay stated Novo Ventures, which had invested in one other firm he had led, approached him with curiosity in coming into the gout house. Given Mackay’s expertise in gout, they needed his expertise and experience.
“We mainly went out and did a panorama search of all of the molecules beneath growth,” he stated. “We recognized dotinurad because the one which we felt had one of the best security and efficacy profile. And we approached Urica Therapeutics and in the end persuaded them that we must always do an asset buy of the license from Fuji.”
In July 2024, Urica bought rights to dotinurad to Crystalys for 35% of the younger biotech’s excellent fairness, in keeping with Fortress regulatory filings. The settlement additionally places Urica in line for a 3% royalty on future internet gross sales of the drug.
Dotinurad might assist fill the hole in second-line gout therapy, the place therapy choices are dwindling. Apart from the market withdrawal of Ardea’s medicine, Takeda Pharmaceutical’s febuxostat, model identify Uloric, is exiting the market. This drug, which affords a mechanism of motion just like allopurinol, received FDA approval in 2009. A decade later, the FDA added a black field warning to Uloric’s label flagging the larger threat of cardiovascular problems, together with dying. Takeda has determined to discontinue the product, which presently faces generic competitors. In line with FDA data, Takeda will stop Uloric distribution in March 2026.
Amgen drug Krystexxa is offered as a third-line gout therapy. This drugs is an engineered model of the enzyme that breaks down uric acid. However Krystexxa should be administered intravenously. One other limitation is that sufferers’ immune methods can produce antibodies that finally render the biologic drug ineffective.
There are different firms growing URAT1 inhibitors that would probably compete with Crystalys’s dotinurad. San Diego-based Arthrosi Therapeutics’ contender is AR882; China-based Atom Therapeutics is growing ABP-671. Each are in Part 3 growth. If these medicine are primarily based on the identical molecular spine as Adrea’s withdrawn Zurampic, they’ll possible have the identical renal toxicity points, Mackay stated. Higher security for dotinurad is a part of the design of the molecule.
Analysis in URAT1 inhibition to deal with gout dates to the Nineteen Seventies, with the event of a molecule known as benzbromarone. This drug received regulatory approvals in some international locations, however by no means the U.S. Benzbromarone was hampered by reviews of liver toxicity. Mackay stated Fuji Yakuhin’s chemists designed dotinurad to take away the renal toxicity points seen with earlier URAT1 inhibitors. Their work additionally eliminated the hepatotoxicity noticed with benzbromarone.
Dotinurad is extremely particular to the URAT1 protein, leaving different renal transporters unaffected, Mackay stated. Consequently, there’s a extra managed launch of uric acid over 24 hours. Different URAT1 inhibitors have proven a spike in uric acid excretion, Mackay stated. Pushing out an excessive amount of uric acid by the kidney in a brief time frame ends in crystallization of uric acid that damages the kidney, he defined.
“We consider [dotinurad] doesn’t have that legal responsibility and there’s no requirement within the Japanese or the Chinese language label for renal monitoring,” Mackay stated. “And clearly the Japanese have given it to over 1,000,000 sufferers since launch and no renal poisonous sign has been recognized.”
Crystalys’s financing, a Sequence A spherical, was co-led by Novo Holdings, SR One, and Catalys Pacific. Different individuals embrace Perceptive Xontogeny Enterprise Funds, Lightstone VC, AN Enterprise Companions, funds managed by abrdn Inc., KB Investments, Pontifax, Longwood Fund, Alexandria Enterprise Investments, Wedbush Healthcare Companions, and Prebys Ventures Fund.
With the brand new capital, Crystalys will advance dotinurad straight to 2 Part 3 research, one assessing the drug’s impact on gout flares and the opposite testing tophus decision. Given the intensive scientific trial and real-world information for the drug in Asia, the FDA is allowing Crystalys to skip Part 2 testing, Mackay stated. The one stipulation is that the FDA needs to see some stage of dose ranging within the Part 3 program, so one of many research will consider a 2 mg dose and a 4 mg dose. The research have a focused enrollment of about 750 sufferers whole. Mackay expects information from these trials in late 2027.
Photograph by Flickr person handarmdoc through a Artistic Commons license